Baseline characteristics of participants

ParameterAll participants
(n = 56)
Lysozyme group
(n = 26)
Control group
(n = 30)
p-value lysozyme vs. control group
Age, years*65 (57–68)66 (59–70)64 (54–68)0.370
Sex, male50 (89)25 (96)25 (83)0.200
Number of days from radiotherapy start to enrollment14 (± 6)14 (± 7)14 (± 6)0.721
Tumor site0.400
Oral cavity20 (35.7)7 (26.9)13 (43.3)
Larynx19 (33.9)9 (34.6)10 (33.3)
Pharynx12 (21.4)7 (26.9)5 (16.7)
Larynx, pharynx4 (7.1)3 (11.5)1 (3.3)
Nasal cavity1 (1.8)0 (0.0)1 (3.3)
T stage> 0.900
02 (3.6)1 (3.8)1 (3.3)
11 (1.8)1 (3.8)0 (0.0)
213 (23.2)6 (23.1)7 (23.3)
317 (30.4)8 (30.8)9 (30.0)
48 (14.3)3 (11.5)5 (16.7)
4a10 (17.9)4 (15.4)6 (20.0)
4b4 (7.1)2 (7.7)2 (6.7)
X1 (1.8)1 (3.8)0 (0.0)
N category0.200
018 (32.1)12 (46.2)6 (20.0)
15 (8.9)3 (11.5)2 (6.7)
210 (17.9)4 (15.4)6 (20.0)
2b11 (19.6)2 (7.7)9 (30.0)
2c3 (5.4)2 (7.7)1 (3.3)
38 (14.3)3 (11.5)5 (16.7)
3b1 (1.8)0 (0.0)1 (3.3)
M category0.700
053 (94.6)24 (92.3)29 (96.7)
12 (3.6)1 (3.8)1 (3.3)
X1 (1.8)1 (3.8)0 (0.0)

Data are presented as mean (± standard deviation); * median (interquartile range, IQR), or as an absolute number (percentage of the total number of respondents in the subject group)